Advanced search
1 file | 634.30 KB

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)

(2011) ANNALS OF ONCOLOGY. 22(5). p.1154-1163
Author
Organization
Abstract
BACKGROUND: We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL). PATIENTS AND METHODS: At predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC-Radiation Therapy Oncology Group Late Effects Normal Tissue-Subjective, Objective, Management, Analytic scale was used for clinicians' assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose. RESULTS: Over the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all P < 0.005). CONCLUSION: Patients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.
Keywords
quality of life, small-cell lung cancer, FOLLOW-UP, NEUROCOGNITIVE FUNCTION, RADIATION-THERAPY, RANDOMIZED-TRIAL, BRAIN METASTASES, CHEMOTHERAPY, CARCINOMA, ONCOLOGY, LUNG-CANCER, prophylactic cranial irradiation, neurocognitive evaluation, phase III clinical trial, limited disease, COMPLETE REMISSION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 634.30 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Le Péchoux, C, A Laplanche, C Faivre-Finn, T Ciuleanu, R. Wanders, D Lerouge, R Keus, et al. 2011. “Clinical Neurological Outcome and Quality of Life Among Patients with Limited Small-cell Cancer Treated with Two Different Doses of Prophylactic Cranial Irradiation in the Intergroup Phase III Trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).” Annals of Oncology 22 (5): 1154–1163.
APA
Le Péchoux, C., Laplanche, A., Faivre-Finn, C., Ciuleanu, T., Wanders, R., Lerouge, D., Keus, R., et al. (2011). Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). ANNALS OF ONCOLOGY, 22(5), 1154–1163.
Vancouver
1.
Le Péchoux C, Laplanche A, Faivre-Finn C, Ciuleanu T, Wanders R, Lerouge D, et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). ANNALS OF ONCOLOGY. 2011;22(5):1154–63.
MLA
Le Péchoux, C, A Laplanche, C Faivre-Finn, et al. “Clinical Neurological Outcome and Quality of Life Among Patients with Limited Small-cell Cancer Treated with Two Different Doses of Prophylactic Cranial Irradiation in the Intergroup Phase III Trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).” ANNALS OF ONCOLOGY 22.5 (2011): 1154–1163. Print.
@article{2047330,
  abstract     = {BACKGROUND: We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL).
PATIENTS AND METHODS: At predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC-Radiation Therapy Oncology Group Late Effects Normal Tissue-Subjective, Objective, Management, Analytic scale was used for clinicians' assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose.
RESULTS: Over the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all P {\textlangle} 0.005).
CONCLUSION: Patients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.},
  author       = {Le P{\'e}choux, C and Laplanche, A and Faivre-Finn, C and Ciuleanu, T and Wanders, R. and Lerouge, D and Keus, R and Hatton, M and Videtic, GM and Senan, S and Wolfson, A and Jones, R and Arriagada, R and Quoix, E and Dunant, A  and Prophylactic Cranial Irradiation (PCI) Collaborative Group,   and Van Meerbeeck, Jan},
  issn         = {0923-7534},
  journal      = {ANNALS OF ONCOLOGY},
  keyword      = {quality of life,small-cell lung cancer,FOLLOW-UP,NEUROCOGNITIVE FUNCTION,RADIATION-THERAPY,RANDOMIZED-TRIAL,BRAIN METASTASES,CHEMOTHERAPY,CARCINOMA,ONCOLOGY,LUNG-CANCER,prophylactic cranial irradiation,neurocognitive evaluation,phase III clinical trial,limited disease,COMPLETE REMISSION},
  language     = {eng},
  number       = {5},
  pages        = {1154--1163},
  title        = {Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)},
  url          = {http://dx.doi.org/10.1093/annonc/mdq576},
  volume       = {22},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: